Crescent Biopharma schedules presentations at September 2026 investor conferences, showcasing advancements in cancer therapies. Webcasts available online.
Quiver AI Summary
Crescent Biopharma, Inc., a clinical-stage biotechnology company focused on cancer therapies, announced its upcoming presentations at two investor conferences in September 2026. The company will participate in a fireside chat at the Cantor Global Healthcare Conference on September 10 and at the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, both in New York. Live webcasts of the events will be available on their website, with replays accessible for 90 days. Crescent Biopharma's pipeline features a PD-1 x VEGF bispecific antibody and innovative antibody-drug conjugates, aiming to develop transformative treatment options for various solid tumors.
Potential Positives
- Management will present at two notable investor conferences, which could enhance visibility and attract potential investors.
- The company's focus on advancing therapies for cancer aligns with significant market demand, positioning Crescent as a key player in oncology.
- The clinical-stage pipeline includes innovative treatments, such as a PD-1 x VEGF bispecific antibody, indicating potential for breakthrough therapies.
Potential Negatives
- There is no new information about clinical trial results or advancements in therapies, which might indicate a lack of significant progress or updates in the company's development pipeline.
FAQ
What events will Crescent Biopharma present at in September 2026?
Crescent Biopharma will present at the Cantor Global Healthcare Conference and Morgan Stanley Global Healthcare Conference.
When is Crescent Biopharma's presentation at the Cantor Global Healthcare Conference?
The presentation is scheduled for September 10, 2026, at 1:35 p.m. ET.
Where can I watch the Crescent Biopharma presentations?
The presentations will be available via live webcast on the Company's Investors section of their website.
What is Crescent Biopharma's focus in oncology?
Crescent Biopharma is dedicated to developing innovative therapies for cancer patients, including antibody-drug conjugates and bispecific antibodies.
How can I contact Crescent Biopharma for investor inquiries?
You can contact Amy Reilly, the Chief Communications Officer, at [email protected].
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CBIO Insider Trading Activity
$CBIO insiders have traded $CBIO stock on the open market 8 times in the past 6 months. Of those trades, 1 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $CBIO stock by insiders over the last 6 months:
- FUNDS MANAGEMENT LLC FAIRMOUNT purchased 853,450 shares for an estimated $12,375,025
- JOSHUA T BRUMM (Chief Executive Officer) sold 42,305 shares for an estimated $761,066
- JONATHAN MCNEILL (President and COO) sold 20,549 shares for an estimated $369,676
- JAN PINKAS (Chief Scientific Officer) sold 1,288 shares for an estimated $23,171
- ELLIE EUNKYUNG IM (Chief Medical Officer) sold 1,219 shares for an estimated $21,929
- BARBARA HARLIN BISPHAM (See Remarks) sold 1,218 shares for an estimated $21,911
- RICHARD WILLIAM SCALZO (Chief Financial Officer) sold 1,112 shares for an estimated $20,004
- RYAN LYNCH (See Remarks) sold 465 shares for an estimated $8,365
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$CBIO Hedge Fund Activity
We have seen 48 institutional investors add shares of $CBIO stock to their portfolio, and 33 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- LOGOS GLOBAL MANAGEMENT LP added 1,417,500 shares (+293.8%) to their portfolio in Q2 2026, for an estimated $25,515,000
- BLACKROCK, INC. added 1,156,037 shares (+999.0%) to their portfolio in Q2 2026, for an estimated $20,808,666
- BOXER CAPITAL MANAGEMENT, LLC removed 453,686 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $8,334,211
- DEEP TRACK CAPITAL, LP removed 453,686 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $8,166,348
- REMEDIUM CAPITAL PARTNERS, LLC added 361,250 shares (+inf%) to their portfolio in Q2 2026, for an estimated $6,502,500
- AMERIPRISE FINANCIAL INC added 302,568 shares (+inf%) to their portfolio in Q2 2026, for an estimated $5,446,224
- DRIEHAUS CAPITAL MANAGEMENT LLC removed 302,457 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $5,556,135
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Full Release
WALTHAM, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in September:
-
2026 Cantor Global Healthcare Conference,
fireside chat on Thursday, September 10, 2026 at 1:35 p.m. ET in New York.
-
Morgan Stanley 24
th
Annual Global Healthcare Conference,
fireside chat on Monday, September 14, 2026 at 5:35 p.m. ET in New York.
A live webcast of each presentation will be available in the Investors section of the Company's website at
https://investors.crescentbiopharma.com/events-presentations
, and a replay will be accessible for 90 days.
About Crescent Biopharma
Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies as single agents and as part of combination regimens to treat a range of solid tumors. For more information, visit
www.crescentbiopharma.com
and follow the Company on
LinkedIn
and
X
.
Contacts
Investors
Amy Reilly
Chief Communications Officer
[email protected]
617-465-0586
Media
Jenna Poist
Director, Corporate Communications
[email protected]
781-671-5019
